Testing NVG-2089 for immune thrombocytopenia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an investigational drug called NVG-2089 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if it safely raises platelet counts and improves bleeding symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have had ITP for more than 3 months (persistent) or more than 12 months (chronic).
- Your last treatment for ITP must have worked at least once (platelet count rose to 50,000 or more).
- You currently have a low platelet count (50,000 or below) and have mild or no bleeding symptoms.
- You have not had your spleen removed.
- You are not pregnant, nursing, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
This trial tests a new drug called ESG206 for adults with immune thrombocytopenia (ITP) whose platelet counts remain very low despite previous treatments like steroids or IVIG. The goal is to see if ESG206 can safely help raise platelet levels and reduce bleeding risk.
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
This trial tests a new mRNA-based medicine called RXIM002 for people with immune thrombocytopenia (ITP) that has not improved with standard treatments. The goal is to see if it can safely help raise platelet counts and reduce bleeding risk.
This trial tests a new drug called GL-2045 for immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing low platelet counts and bleeding risks. The study checks if GL-2045 is safe and effective for people whose platelet counts haven't been controlled well enough with other treatments.
This trial tests if a substance called NAD can help adults with immune thrombocytopenia (ITP) whose platelet levels stay low even after standard treatments. ITP is a condition where the immune system attacks platelets, causing easy bruising and bleeding. The study aims to see if NAD can safely raise platelet counts.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.